Renalytix (RENX) investor relations material

Executive summary

• Revenue for the six months ended 31 December 2025 increased to $1.6 million from $1.3 million year-over-year, driven by expanded clinical adoption and integration of kidneyintelX.dkd.

• 58 new practice sites and over 135 new physicians onboarded, with integration into five EHR systems, up from two in the prior year.

• Underlying EBITDA loss reduced to $6.4 million from $7.2 million, reflecting disciplined cost management.

• Transition to a new laboratory facility commenced to enhance capacity and improve gross margin.

• $9.5 million raised through an over-subscribed placing and retail offer at a premium to the prior six-month share price.

Financial highlights

• Total revenue for HY26 was $1.6 million (HY25: $1.3 million), with life sciences revenue rising to $0.5 million (HY25: $0.1 million) and commercial test revenue at $1.1 million (HY25: $1.2 million).

• Cost of sales remained flat at $0.8 million year-over-year.

• Administrative costs decreased to $7.9 million from $8.0 million.

• Operating loss for HY26 was $7.1 million (HY25: $7.5 million).

• Net loss for the period was $8.1 million, with basic and diluted loss per share of $0.02 (HY25: $0.05).

Outlook and guidance

• Full-year revenue expected to be approximately $4 million, reflecting timing and complexity of EMR integrations rather than reduced demand.

• Anticipates revenue acceleration in H2 FY26 as integrations mature and distribution expands.

• National distribution agreement targeted for 2026 to drive significant uptake and reduce capital expenditure.